In a message sent out to investors on Thursday, the research analysts at StockNews.com stated that they had assumed coverage on Boston Scientific (NYSE: BSX).
The company has provided its shareholders with a recommendation to “buy” the stock of the medical equipment supplier.
On February 1, Boston Scientific released its most recent quarterly earnings report.
Boston Scientific is a publicly traded company on the NYSE, and its stock is denoted by the symbol BSX.
The company that manufactures medical equipment reported earnings per share for the quarter of $0.45, which was $0.02 less than the consensus estimate of $0.47 from market experts.
The market experts’ estimates were based on the company earning $0.47 per share.
The revenue for the quarter came in at $3.24 billion, which is on par with the expectations generally held for that amount to be the case.
The net margin for Boston Scientific was calculated to be 5.50 percent, and the return on equity for the company was 14.29 percent. Compared to the numbers for the same period in the previous year, Boston Scientific reported a 3.7% increase in the company’s quarterly revenue.
In the same period as the previous year, the corporation made a profit of $0.45 per share of common stock.
Equity research analysts forecast that Boston Scientific will generate a 1.9 cents per share profit during the current financial year.
A single share of BSX stock was valued at $47.97 at the start of trading on Thursday.
The organization is profitable, as evidenced by its market valuation of $68.83 billion, its price-to-earnings ratio of 106.60, its price-to-earnings-to-growth ratio of 2.19, and its beta value of 0.79.
Additionally, the organization has a beta value of 0.79, which indicates that it is not overly sensitive to changes in the market.
The price of a share of Boston Scientific’s stock has ranged from a low of $34.98 to a high of $48.87 over the past 52 weeks.
The moving average for the stock over the past 50 days is $46.77, and the moving average for the past 200 days is $44.13, respectively.
The quick ratio is 1.02, the current ratio is 1.51, and the debt-to-equity ratio is 0.51.
All of these numbers are relative to the total amount of debt.
All these figures should be interpreted in light of the overall sum owed.
Recently, several research analysts have published the results of their investigations into the company in the form of research studies. Needham & Company LLC raised their target price on Boston Scientific from $48.00 to $53.00 and assigned a “buy” rating in a research note published on Thursday, February 2.
In a research note made available to the general public on December 22, Mizuho announced they would cover Boston Scientific going forward.
They have provided the company with a ” neutral ” rating and projected that the share price would reach $52.00 shortly.
In a research report released on Thursday, February 2, JPMorgan Chase & Co increased their target price on Boston Scientific from $48.00 to $55.00 and gave the company an “overweight” rating. On Tuesday, December 20, Citigroup announced in a research note that it would begin covering Boston Scientific.
The announcement came on Tuesday.
They suggested investing in the company’s stock and established a price target of $54.00 for it.
In a research note published on Thursday, February 2, Raymond James increased their price target on Boston Scientific from $54.00 to $56.00 and rated the company’s stock as a “strong buy.” The note titled “Thursday Research Update” discussed how the company had performed recently. One research analyst suggests purchasing the stock; thirteen other industry experts concur that purchasing the stock is the best course of action; and one research analyst suggests making a strong purchase.
According to the data provided by Bloomberg, the current recommendation for the company is “Buy,” and analysts have set a price objective of $51.50 as the average for the stock’s price.
In other news, on March 1, Jonathan Monson, currently serving as the company’s chief operating officer, sold 5,000 of the company’s shares that he owned in his portfolio.
The stock sale generated a total revenue of $233,300.00, with the average price at which each share was sold being $46.66.
As a result of the completion of the sale, the chief accounting officer now directly owns a total of 34,868 shares of the company, which have a value of $1,626,940.88.
If you follow this link, you will be taken to the filing submitted to the Securities and Exchange Commission, where the transaction was discussed, and it will take you there immediately.
In other news, on March 1, Jonathan Monson, currently serving as the company’s chief operating officer, sold 5,000 of the company’s shares that he owned in his portfolio.
The stock sale generated a total revenue of $233,300.00, with the average price at which each share was sold being $46.66.
As a result of the completion of the sale, the chief accounting officer now directly owns a total of 34,868 shares of the company, which have a value of $1,626,940.88. Following this link will show the filing submitted to the Securities and Exchange Commission and where the transaction was discussed. You can simply ignore this link if you do not want to follow it.
Daniel J.
Brennan, the company’s Chief Financial Officer, sold 75,610 shares of the company’s stock on March 1 as well.
The total value of the shares was determined to be $3,526,450.40, equivalent to a price of $46.64 per share after they were sold.
Because of the sale, the chief financial officer now owns 255,958 shares.
The combined value of these shares is $11,937,881, so the CFO’s stake in the business has increased significantly.
Twelve disclosures related to the sale might be found in this section of the website.
Insiders of the company sold 115,182 shares of company stock during the most recent quarter for a total value of $5,432,674, as reported in the most recent quarterly report.
These sales account for 0.66 percent of the total shares held by the company’s executives, directors, and key employees.
Recent months have seen several institutional investors, including hedge funds and other types of investment funds, adjust the overall number of shares held in their portfolios.
Montag A & Associates INC increased the amount of Boston Scientific stock owned by 8.5% over the final three months of 2018.
Montag A & Associates INC has a total of 2,712 shares in the medical equipment company at this time, and those shares are now worth $125,000 thanks to the purchase of 212 additional shares during the relevant period. Childress Capital Advisors LLC made a 3.5% purchase of additional Boston Scientific shares during the fourth quarter, bringing the total number of shares it owned in that company to 95.5%. Following the acquisition of 212 additional shares during the most recent quarter, Childress Capital Advisors LLC now holds 6,201 shares in the medical equipment provider.
The current market value of these shares is $287,000.
In the last three months of 2018, Hazlett Burt & Watson INC accumulated a 56.7% increase in the number of Boston Scientific shares it owned. Hazlett Burt & Watson INC now has 636 shares of the medical equipment provider’s stock, valued at $30,000, following the purchase of an additional 230 shares during the most recent quarter. Zions Bancorporation N.A.
Increased the amount of Boston Scientific stock owned by 14.8% over the final three months of 2018. Zions Bancorporation N.A. now has 1,793 shares of the medical equipment provider’s stock after purchasing an additional 231 shares during the most recent quarter.
The stock has a current value of $83,000, and Zions Bancorporation N.A.’s investment in it was increased by $83,000.
And finally, during the final three months of 2018, Vestcor INC added 0.8% more Boston Scientific stock to its holdings, bringing its total to 100%. Vestcor INC increased the total number of shares it owns in the medical equipment provider to 33,955 at the beginning of the most recent fiscal quarter by purchasing 278 additional shares.
The total value of these shares comes to $1,571,000.
Institutional investors and hedge funds currently own 90.23 percent of the company’s stock between them.